Bangladesh - English - DGDA (Directorate General of Drug Administration)

globex pharmaceuticals ltd. - cefixime - capsule - 200 mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

globex pharmaceuticals ltd. - cefixime - powder for suspension - 200 mg/5 ml

Uganda - English - National Drug Authority

globela pharma pvt. ltd. - loperamide hydrochloride - oral solid ordinary capsules - 2mg

Bangladesh - English - DGDA (Directorate General of Drug Administration)

globe pharmaceuticals ltd. - zinc - syrup - 10 mg/5 ml

Bangladesh - English - DGDA (Directorate General of Drug Administration)

globe pharmaceuticals ltd. - zinc - tablet - 20 mg

Canada - English - Health Canada

globe commercial products inc. - benzalkonium chloride - wipe - 0.26% - benzalkonium chloride 0.26% - disinfectants (for agents used on object)

Israel - English - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ketamine as hydrochloride - solution for injection / infusion - ketamine as hydrochloride 10 mg/ml - ketamine - ketamine - as the sole anaesthetic agent for diagnostic and surgical procedures. when used by intravenous or intramuscular injection, ketalar is best suited for short procedures. with additional doses, or by intravenous infusion, ketalar can be used for longer procedures. if skeletal muscle relaxation is desired a muscle relaxant should be used and respiration should be supported. for the induction of anaesthesia prior to the administration of other general anaesthetic agents. to supplement other anaesthetic agents. specific areas of application or types of procedure: when the intramuscular route of administration is preferred. debridement, painful dressings and skin grafting in burned patients as well as other superficial surgical procedures. neurodiagnostic procedures such as pneumoencephalograms, ventriculograms, myelograms and lumbar punctures. diagnostic and operative procedures of the eye, ear, nose and mouth including dental extractions.( note: eye movement may persist during ophthalmological procedures). anaesthesia in poor-risk patients with depression of vital functions or where depression of vital functions must be avoided if at all possible. orthopaedic procedures such as closed reduction, manipulation femoral pinning, amputations and biopsies. sigmoidoscopy and minor surgery of the anus and rectum, circumcision and pilonidal sinus. cardiac catheterization procedures. caesarian section: as an induction agent in the absence of elevated blood pressure. anaesthesia in the asthmatic patient, either to minimise the risk of an attack of bronchospasm developing or in the presence of bronchospasm where anaesthesia cannot be delayed.

United States - English - NLM (National Library of Medicine)

butler animal health supply - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), bacitracin zinc (unii: 89y4m234es) (bacitracin - unii:58h6rwo52i), hydrocortisone (unii: wi4x0x7bpj) (hydrocortisone - unii:wi4x0x7bpj) - neomycin sulfate 3.5 mg in 1 g - neomycin and polymyxin b sulfates, bacitracin zinc and hydrocortisone ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see clinical pharmacology: microbiology). the particular anti-infective drugs in this product

United States - English - NLM (National Library of Medicine)

phoenix pharmaceutical, inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin sulfate 3.5 mg in 1 g - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain cases of infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drugs in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, klebsiella/ente

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - neomycin sulfate (unii: 057y626693) (neomycin - unii:i16qd7x297), polymyxin b sulfate (unii: 19371312d4) (polymyxin b - unii:j2vz07j96k), dexamethasone (unii: 7s5i7g3jql) (dexamethasone - unii:7s5i7g3jql) - neomycin 3.5 mg in 1 ml - for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. ocular corticosteroids are indicated in inflammatory conditions of the papebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. they are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. the use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. the particular anti-infective drug in this product is active against the following common bacterial eye pathogens: staphylococcus aureus, escherichia coli, haemophilus influenzae, kleb